Ameriprise
DBVT

Ameriprise’s DBV Technologies DBVT Stock Holding History

Ameriprise’s Portfolio DBVT Stock Details DBVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.21M Buy
378,497
+147,080
+64% +$2.78M ﹤0.01% 2404
2026
Q1 		$4.83M Buy
+231,417
New +$4.83M ﹤0.01% 2453
2024
Q2 		– Sell
-110,972
Closed -$839K – 3880
2024
Q1 		$839K Sell
110,972
-335
-0.3% -$2.85K ﹤0.01% 3240
2023
Q4 		$1.06M Sell
111,307
-3,133
-3% -$30.4K ﹤0.01% 3164
2023
Q3 		$1.56M Sell
114,440
-3,942
-3% -$61.8K ﹤0.01% 2949
2023
Q2 		$2.25M Sell
118,382
-1,880
-2% -$34K ﹤0.01% 2814
2023
Q1 		$2.03M Sell
120,262
-4,182
-3% -$61.9K ﹤0.01% 2839
2022
Q4 		$1.91M Sell
124,444
-4,976
-4% -$73.2K ﹤0.01% 2834
2022
Q3 		$2.29M Sell
129,420
-240
-0.2% -$5.56K ﹤0.01% 2723
2022
Q2 		$3.3M Sell
129,660
-879
-0.7% -$14.7K ﹤0.01% 2563
2022
Q1 		$2.08M Buy
130,539
+2,802
+2% +$42.3K ﹤0.01% 2895
2021
Q4 		$2.04M Buy
127,737
+535
+0.4% +$18.1K ﹤0.01% 2951
2021
Q3 		$6.23M Sell
127,202
-5,483
-4% -$283K ﹤0.01% 2235
2021
Q2 		$7.26M Sell
132,685
-125
-0.1% -$7.48K ﹤0.01% 2179
2021
Q1 		$7.08M Buy
132,810
+24,191
+22% +$1.28M ﹤0.01% 2152
2020
Q4 		$2.85M Buy
108,619
+18,891
+21% +$418K ﹤0.01% 2616
2020
Q3 		$1.55M Buy
89,728
+6,099
+7% +$175K ﹤0.01% 2793
2020
Q2 		$3.67M Buy
83,629
+22,829
+38% +$1.17M ﹤0.01% 2281
2020
Q1 		$2.38M Buy
60,800
+5,489
+10% +$492K ﹤0.01% 2387
2019
Q4 		$5.92M Buy
55,311
+25,382
+85% +$2.03M ﹤0.01% 2129
2019
Q3 		$2.57M Sell
29,929
-612
-2% -$58.3K ﹤0.01% 2583
2019
Q2 		$2.51M Sell
30,541
-126
-0.4% -$11.3K ﹤0.01% 2609
2019
Q1 		$2.36M Sell
30,667
-442
-1% -$33.6K ﹤0.01% 2665
2018
Q4 		$2M Buy
31,109
+4,336
+16% +$698K ﹤0.01% 2648
2018
Q3 		$6.01M Buy
26,773
+1,094
+4% +$222K ﹤0.01% 2229
2018
Q2 		$4.95M Buy
25,679
+14,460
+129% +$3.26M ﹤0.01% 2251
2018
Q1 		$2.59M Buy
11,219
+6,197
+123% +$1.46M ﹤0.01% 2587
2017
Q4 		$1.24M Buy
+5,022
New +$1.45M ﹤0.01% 2882

Other funds holding DBVT

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return

Ameriprise's DBVT Position: Q2 2026 in Review

Ameriprise increased its DBV Technologies (DBVT) stake by 64% in Q2 2026, buying an estimated $2.78M and bringing the position to 378,497 shares worth $6.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2404.

Ameriprise first reported a position in DBVT in Q4 2017 and has held it in 28 quarters since. The position peaked at $7.26M in Q2 2021. 78 funds tracked by Wall St. Rank hold DBVT as of Q2 2026.

  • Ameriprise held 378,497 shares of DBV Technologies worth $6.21M as of Q2 2026.
  • Ameriprise bought 147,080 DBV Technologies shares in Q2 2026, an estimated $2.78M.
  • DBV Technologies made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2404 holding.
  • Ameriprise first reported a position in DBV Technologies in Q4 2017 and has held it in 28 quarters since.
  • Ameriprise's DBV Technologies position peaked at $7.26M in Q2 2021.
  • 78 funds tracked by Wall St. Rank held DBV Technologies as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.